Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer-BioNTech COVID-19 Vaccine in Medical Employees

Article Medicine, General & Internal

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Devan Mehrotra et al.

Summary: Several COVID-19 vaccine candidates are entering large-scale phase 3 clinical trials with proposed general clinical endpoint measures to facilitate evaluation and comparison. The potential shift towards more asymptomatic SARS-CoV-2 infections alongside vaccine protection against symptomatic COVID-19 is highlighted, along with its implications.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

Andrew Letizia et al.

Summary: Young adults with SARS-CoV-2 antibodies have about one-fifth the risk of subsequent infection compared to those without antibodies. While antibodies from initial infection offer protection, they do not guarantee effective neutralization or immunity against future infection. These findings could impact mass vaccination strategies.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Sharon Amit et al.

Summary: A study found that breakthrough infections among fully vaccinated healthcare workers are limited, with no evidence of secondary transmission in most cases. Despite some breakthrough infections, the proportion of such cases is relatively low among fully vaccinated healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Gastroenterology & Hepatology